Addex Therapeutics Ltd. ADXN
Addex Therapeutics Ltd. (Nasdaq: ADXN) is a CNS/neurology/psychiatry drug developer. Its lead program, Dipraglurant (mGlu5 NAM), is in Pre-clinical for Post-stroke / traumatic brain injury recovery.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Dipraglurant (mGlu5 NAM) | Post-stroke / TBI recovery (in vivo stroke-model testing; Phase 2a planned subject to funding or partner) | small molecule | Pre-clinical |
| ADX71149 (mGlu2 PAM) | Indications under evaluation; returned by Janssen April 2025 | small molecule | Pre-clinical |
| GABAB PAM (substance use disorders) | Substance use disorders incl. alcohol use disorder; IND-enabling studies completed; returned from Indivior Sept 2026 | small molecule | Pre-clinical |
| GABAB PAM (chronic cough) | Refractory chronic cough | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.